Cargando…

Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital

Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver diseases, including liver cirrhosis, liver cell failure, and hepatocellular carcinoma. The HCV has seven major genotypes. Genotype 4 is the most prevalent genotype in the Middle East, including Saudi Arab...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawsawi, Nahed Mohammed, Saber, Tamer, Salama, Hussein M., Fouad, Walaa S., Hagag, Howaida M., Alhuthali, Hayaa M., Eed, Emad M., Saber, Taisir, Ismail, Khadiga A., Al Qurashi, Hesham H., Altowairqi, Samir, Samaha, Mohmmad, El-Hossary, Dalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967136/
https://www.ncbi.nlm.nih.gov/pubmed/36828508
http://dx.doi.org/10.3390/tropicalmed8020092
_version_ 1784897189949997056
author Hawsawi, Nahed Mohammed
Saber, Tamer
Salama, Hussein M.
Fouad, Walaa S.
Hagag, Howaida M.
Alhuthali, Hayaa M.
Eed, Emad M.
Saber, Taisir
Ismail, Khadiga A.
Al Qurashi, Hesham H.
Altowairqi, Samir
Samaha, Mohmmad
El-Hossary, Dalia
author_facet Hawsawi, Nahed Mohammed
Saber, Tamer
Salama, Hussein M.
Fouad, Walaa S.
Hagag, Howaida M.
Alhuthali, Hayaa M.
Eed, Emad M.
Saber, Taisir
Ismail, Khadiga A.
Al Qurashi, Hesham H.
Altowairqi, Samir
Samaha, Mohmmad
El-Hossary, Dalia
author_sort Hawsawi, Nahed Mohammed
collection PubMed
description Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver diseases, including liver cirrhosis, liver cell failure, and hepatocellular carcinoma. The HCV has seven major genotypes. Genotype 4 is the most prevalent genotype in the Middle East, including Saudi Arabia, followed by genotype 1. The HCV genotype affects the response to different HCV treatments and the progression of liver disease. Currently, combinations of direct-acting antiviral drugs (DAAs) approved for the treatment of HCV achieve high cure rates with minimal adverse effects. Because real-world data from Saudi Arabia about the efficacy of DAAs are still limited, this study was conducted to assess the effectiveness of DAAs in treating patients with chronic hepatitis C and to identify the variables related to a sustained virologic response (SVR) in a real-world setting in Saudi Arabia. This prospective cohort study included 200 Saudi patients with chronic HCV who were 18 years of age or older and had been treated with DAAs at King Abdul-Aziz Specialized Hospital in Taif, Saudi Arabia, between September 2018 and March 2021. The response to treatment was assessed by whether or not an SVR had been achieved at week 12 post treatment (SVR12). An SVR12 was reached in 97.5% of patients. SVR12 rates were comparable for patients of different ages, between men and women, and between patients with and without cirrhosis. In addition, the SVR12 rates did not differ according to the infecting HCV genotype. In this study, the presence of cirrhosis and the patient’s gender were independent predictors of who would not reach an SVR12 (known here as the non-SVR12 group) according to the results of univariate and multivariate binary logistic regression analyses based on the determinants of SVR12. In this population of patients with chronic HCV infection, all DAA regimens achieved very high SVR12 rates. The patients’ gender and the presence of cirrhosis were independent factors of a poor response.
format Online
Article
Text
id pubmed-9967136
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99671362023-02-26 Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital Hawsawi, Nahed Mohammed Saber, Tamer Salama, Hussein M. Fouad, Walaa S. Hagag, Howaida M. Alhuthali, Hayaa M. Eed, Emad M. Saber, Taisir Ismail, Khadiga A. Al Qurashi, Hesham H. Altowairqi, Samir Samaha, Mohmmad El-Hossary, Dalia Trop Med Infect Dis Article Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver diseases, including liver cirrhosis, liver cell failure, and hepatocellular carcinoma. The HCV has seven major genotypes. Genotype 4 is the most prevalent genotype in the Middle East, including Saudi Arabia, followed by genotype 1. The HCV genotype affects the response to different HCV treatments and the progression of liver disease. Currently, combinations of direct-acting antiviral drugs (DAAs) approved for the treatment of HCV achieve high cure rates with minimal adverse effects. Because real-world data from Saudi Arabia about the efficacy of DAAs are still limited, this study was conducted to assess the effectiveness of DAAs in treating patients with chronic hepatitis C and to identify the variables related to a sustained virologic response (SVR) in a real-world setting in Saudi Arabia. This prospective cohort study included 200 Saudi patients with chronic HCV who were 18 years of age or older and had been treated with DAAs at King Abdul-Aziz Specialized Hospital in Taif, Saudi Arabia, between September 2018 and March 2021. The response to treatment was assessed by whether or not an SVR had been achieved at week 12 post treatment (SVR12). An SVR12 was reached in 97.5% of patients. SVR12 rates were comparable for patients of different ages, between men and women, and between patients with and without cirrhosis. In addition, the SVR12 rates did not differ according to the infecting HCV genotype. In this study, the presence of cirrhosis and the patient’s gender were independent predictors of who would not reach an SVR12 (known here as the non-SVR12 group) according to the results of univariate and multivariate binary logistic regression analyses based on the determinants of SVR12. In this population of patients with chronic HCV infection, all DAA regimens achieved very high SVR12 rates. The patients’ gender and the presence of cirrhosis were independent factors of a poor response. MDPI 2023-01-30 /pmc/articles/PMC9967136/ /pubmed/36828508 http://dx.doi.org/10.3390/tropicalmed8020092 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hawsawi, Nahed Mohammed
Saber, Tamer
Salama, Hussein M.
Fouad, Walaa S.
Hagag, Howaida M.
Alhuthali, Hayaa M.
Eed, Emad M.
Saber, Taisir
Ismail, Khadiga A.
Al Qurashi, Hesham H.
Altowairqi, Samir
Samaha, Mohmmad
El-Hossary, Dalia
Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
title Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
title_full Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
title_fullStr Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
title_full_unstemmed Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
title_short Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
title_sort genotypes of hepatitis c virus and efficacy of direct-acting antiviral drugs among chronic hepatitis c patients in a tertiary care hospital
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967136/
https://www.ncbi.nlm.nih.gov/pubmed/36828508
http://dx.doi.org/10.3390/tropicalmed8020092
work_keys_str_mv AT hawsawinahedmohammed genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT sabertamer genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT salamahusseinm genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT fouadwalaas genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT hagaghowaidam genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT alhuthalihayaam genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT eedemadm genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT sabertaisir genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT ismailkhadigaa genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT alqurashiheshamh genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT altowairqisamir genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT samahamohmmad genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital
AT elhossarydalia genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital